Krsnaa Diagnostics Limited shareholders approved all five ordinary resolutions at the company's 16th Annual General Meeting (AGM), including the declaration of a final dividend of ₹2.00 per equity share for FY26.

The meeting, held on September 28, 2026, in Pune, saw the adoption of audited financial statements and the re-appointment of Managing Director Yash Mutha. The disclosure was filed with stock exchanges on September 30, 2026, pursuant to Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Voting results on key resolutions

The scrutinizer's report confirmed that all resolutions were passed with requisite majority. The final dividend resolution received overwhelming support, with 99.9997% of valid votes cast in favour. The appointment of M/s Kirtane & Pandit LLP as statutory auditors for a five-year term also passed, despite receiving 0.43% votes against from institutional and non-institutional public shareholders.

Auditor appointment details

Members appointed M/s Kirtane & Pandit LLP (Firm Registration No. 105215W/W100057) as Statutory Auditor for a first term of 5 consecutive years. The appointment holds office from the conclusion of the 16th AGM until the conclusion of the 21st AGM. The firm has more than 7 decades of experience in audit, Risk Management, and Tax, with service lines spanning IT, Business Process, and ESOP advisory sectors. It holds a valid peer review certificate as on the date of appointment.

Leadership and attendance details

The proceedings were chaired by Rajendra Mutha, Chairperson and Whole Time Director. Sujoy Sudipta Bose, Company Secretary and Compliance Officer, welcomed attendees. Seven directors were present in person, alongside Key Managerial Personnel (KMPs).

The following KMPs attended in person:

• Mitesh Dave: Group Chief Executive Officer
• Chandra Prakash Singh: Interim Chief Financial Officer
• Sujoy Bose: Company Secretary and Compliance Officer

Auditor and scrutinizer representation

Representatives from statutory, secretarial, and cost auditor firms oversaw procedural aspects. Dinesh Birla of M/s Dinesh Birla & Associates served as the Scrutinizer, submitting the consolidated report on September 30, 2026.

What the numbers show

Voting participation remained low relative to the total shareholder base. Out of 51,817 shareholders on record, only 36 attended or voted through proxies. Promoter group voting power stood at 8,795,605 shares, while public institutions polled 4,184,506 votes. The minimal dissent on the auditor appointment (60,783 votes against) suggests general alignment with management proposals, though institutional investors showed slightly higher scrutiny compared to retail non-institutional shareholders.

Krsnaa Diagnostics board has approved the sale of diagnostic equipment worth up to ₹120 crore, a move aimed at improving asset management and capital efficiency.

Board decision on equipment sale

The board of Krsnaa Diagnostics greenlit the disposal of identified diagnostic equipment, with the total transaction value capped at ₹120 crore. The decision reflects the company's focus on optimising its asset base through the structured sale of assets to identified purchasers, including those that may be identified in the future.

Strategic rationale

The board-sanctioned sale is directed at improving asset management within the organisation. By divesting diagnostic equipment up to the approved value, Krsnaa Diagnostics aims to streamline its operational asset portfolio. The proposed transaction forms part of the company’s ongoing strategic initiative to transition towards an increasingly asset-light and capital-efficient operating model.

The company stated that it has identified certain assets that can be monetised without impacting its core operating capabilities. The sale is intended to unlock value from these assets and facilitate efficient recycling of capital towards the core diagnostic business and identified growth opportunities. This initiative is expected to support improved asset utilisation, enhance return on capital employed (ROCE), and strengthen the balance sheet.

Asset details and regulatory compliance

The assets proposed for sale comprise identified freehold assets which are not subject to any security interest created in favour of the company’s lenders. Accordingly, the transaction will not impact the assets forming part of the security package provided to lenders. The board clarified that this exercise is one of active portfolio and capital optimisation and is not driven by any impairment or diminution in the value of the underlying assets.

The transaction does not constitute a sale or disposal of an undertaking within the meaning of Section 180(1)(a) of the Companies Act, 2013. The board authorised the Operations Committee to finalise the terms and conditions of the transaction within the aggregate limit approved.